Lowest Price Guaranteed
Pages
242
Last Updated
June 2026
View Count
15682
The global protein engineering market, valued at USD 0.85 billion in 2025, is projected to reach USD 0.96 billion in 2026 and USD 3.15 billion by 2035, with a 14.1% CAGR during the forecast period 2026 to 2035.
 |
To learn more about this report, request a free sample copy
Protein engineering is a process that involves the manipulation of protein structure to synthesize proteins with desired properties and structures. The protein manipulation technique has been widely used for designing targeted therapies, cell therapies, and protein-based therapies. In the past few years, protein-based therapeutics, including blood factor, monoclonal antibodies, peptide therapeutics, hormones, vaccines, and therapeutic enzymes have caught significant attention owing to the growing demand for targeted therapies. However, the success of these protein-based therapies can be predicted by the clinical significance offered, such as low toxicity, high target specificity, and safety profiles. It is worth mentioning here that protein-based medications have the potential to treat various disease indications, including autoimmune disease, cancer, and genetic disorders.
Further, these targeted therapeutic drugs have been designed to interact with selective targets in the body and show fewer adverse effects. These protein-based medications also show a lower tendency of metabolizing by the liver, which further increases the efficiency of medicine. Driven by the significance offered by protein-based medications, several pharmaceutical companies accelerated their research efforts towards development of novel medicines. It is worth highlighting here that more than 55 protein-based therapies have already been marketed for the treatment of various disease indications.
 |
 |
 |
However, the key developers of protein-based therapies are fraught with several challenges while manufacturing these therapeutics, such as low physical stability, poor chemical stability, and short half-life. In order to overcome these challenges and to ensure the smooth development of protein therapeutics with desired characteristics, several researchers are shifting towards protein engineering techniques. The process involves multistep along with high throughput screening procedures for the isolation and purification of proteins. It is worth mentioning here that the protein engineering process consumes time and investment. Considering these factors, several pharmaceutical companies have begun to outsource protein engineering processes to CMOs or specialized service providers who hold the required expertise to develop desired protein structures. Currently, more than 85 protein engineering companies are active in this industry that support the production of advanced proteins / peptide-based therapeutics. As the demand for protein-based therapeutics increases, the protein engineering industry is expected to grow at a steady rate during the forecast period.
 |
 |
 |
The market report features an in-depth analysis of various companies that are engaged in the industry across different segments, as defined in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | 2026-2035 | |
| Future Trend | Till 2035 | |
| Market Size 2035 | USD 3.15 billion | |
| Market CAGR | ~14.1% | |
| Distribution by Type of Protein Engineering Approach Used |
|
|
| Distribution by Types of Protein |
|
|
| Application Area |
|
|
| Type of End User |
|
|
| Key Geographical Region |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
 |
 |
 |
One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunities for the protein engineering industry during the forecast period. Additionally, it features market size projections for the protein design and engineering services market, wherein both the current and upcoming opportunity is segmented across [A] type of protein engineering approach used (rational designing, directed evolution and semi-rational designing), [B] type of protein (antibodies, peptides, enzymes, vaccines and others), [C] type of application (therapeutics and diagnostics), [D] type of end user (pharma / biotech firms, CROs and research / academic institutes) and [E] key geographies (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry's evolution.
The opinions and insights presented in this market research report were influenced by discussions conducted with multiple stakeholders in the protein engineering market. The market report features detailed transcripts of interviews held with the following individuals:
Based on the type of protein engineering approach used, the market is segmented into rational designing, direct evolution, and semi-rational designing. According to our projection, rational designing currently occupies the largest share of the market and is poised to capture 53% of the overall revenue share by 2035. The highest share is due to the growing usage of rational designing in antibody development and enzyme engineering. With increasing expansion of rational designing in antibody and enzyme engineering to enhance catalytic properties, the trend of growth remains unchanged and rational designing is likely to grow at a higher CAGR of 15% till 2035.
The protein engineering market has been segmented into antibodies, peptides, enzymes, vaccines and others on the basis of the type of proteins. Driven by the growing usage of monoclonal antibodies to develop target specific therapies, the antibodies account for a significant share of the market and is expected to hold 48% of the overall market share by 2035. This can be attributed to the fact that monoclonal antibodies are currently being adopted for treating patients with cancer. It is worth highlighting here that vaccines have shown lucrative growth potential owing to the rising focus of industry leaders on vaccines for treating infectious diseases, representing a higher CAGR of 14.8% during the forecast period.
Based on application area, the market is segmented into therapeutics and diagnostics. As per our projection, therapeutics application accounts to hold largest share of the market and is estimated to hold 78% of revenue share by 2035. The highest market share can be attributed to the growing research on advanced protein-based therapeutics to target wide range of applications beyond cancer treatment. The trend of growth is likely to remain unchanged and therapeutic segment is expected to grow at a higher CAGR of 14.4% during the forecast period.
On the basis of end users, the market is segmented into pharma / biotech firms, CROs, and research / academic institutes. According to our projection, pharma / biotech accounts for the largest protein engineering market share and is poised to capture 61% of overall revenue share by 2035. This is due to the increasing R&D activities to develop drug and growing usage of in silico drug development model to treat patients suffering from cancer, diabetes and neurological problems. It is worth highlighting here that protein designing and development require specialized operational units and technologies due to which several pharmaceutical companies are shifting to contract manufacturing services. Driven by the growing trend of outsourcing, CROs will expand at a healthy CAGR of 14.4% during the forecast period.
The global protein engineering market value has been distributed across North America, Europe, Asia-Pacific, Latin America, MENA, and the rest of the world. According to our projection, North America occupies the largest share and is supposed to capture 32% of the market share by 2035. The highest growth share can be predicted to the fact that several industrial stakeholders and pharmaceutical companies active in this industry are entering to mergers and collaboration partnerships to drive innovation in protein engineering technology and services. It is worth highlighting here that the market in Asia-Pacific is likely to expand at a higher CAGR of 15% during the forecast period.
The “Protein Engineering Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast, and future opportunities for protein engineering companies. The market research report features an in-depth analysis, highlighting the capabilities of protein engineering companies.
Currently, the protein engineering market features over 85 companies that offer the required technical expertise for the development of structured protein. Overall, the market is highly fragmented, featuring the presence of several established, new entrants, small, mid-sized, and large companies. It is worth noting here that nearly 30% of the key players active in this domain provide protein design and engineering services for both therapeutics and diagnostics applications. Notably, the majority of these players are emphasizing on offering their services for the production of engineered antibody-based therapeutics. Furthermore, the growing demand for personalized medicine and targeted specific therapeutics has catered to the attention of established and various other players to drive growth in this field. It is interesting to note here that these companies are steadily expanding their existing capabilities to enhance their respective services portfolios, offering lucrative opportunities to drive future market growth.
Several growth drivers that are propelling the protein engineering market growth include growing demand for personalized medicine and biopharmaceuticals. Engineering proteins play a critical role in optimizing structural protein designs to attain desired properties for the production of monoclonal antibodies, therapeutic proteins, vaccines, and biologics. The engineering protein improves the therapeutic efficiency, specificity, and safety profile of the targeted therapies, which is anticipated to drive the growth of the protein engineering market. As the research continues on advanced biopharmaceutical products that demand customized proteins, the market is estimated to grow at a steady rate during the forecast period.
The growing interest of biopharmaceutical companies towards engineered proteins for the development of novel therapies brings enormous opportunities to accelerate research on technological advancements. It is interesting to note here that the continuous technological advancements in protein engineering technologies such as directed evolution, CRISPR-based approaches, and computational-based protein design have further fueled the growth of this industry during the forecast period. These advanced technologies help to improve precision, efficiency, and high-throughput manipulation of protein functions and structures. In this context, it is worth highlighting here that more than 550 patents associated with protein engineering techniques have been filed / granted in the past few years, representing continuous innovation in this field.
In addition, researchers are focusing on artificial intelligence and computer aided drug discovery methods to optimize protein engineering processes. Integration of these technologies can help in the identification of protein variants, predict accurate protein structure and design with desired properties, thereby enhancing the success rate and efficiency of protein engineering projects. Furthermore, the expanding research activities across different therapeutic applications necessitates specialized protein engineering techniques to meet ongoing experiment requirements, thereby propelling enormous opportunities in this segment.
Given the growing focus on personalized treatment, there has been a rise in partnerships and collaborations between key players to enhance protein engineering services and technology platforms. It is worth noting here that several established and new entrants have signed strategic agreements focused on the research and development of various proprietary candidates. Nearly 43% of the partnerships have been made between the established players in North America. It is interesting to note here that, in March 2024, Navigo Proteins entered into collaboration with Oncodesign Precision Medicine for development of novel radiotherapy agents based on Affilins® technology platform.
Examples of key protein engineering companies (which have also been profiled in this market report; the complete list of protein engineering companies is available in the full report) include ATUM, Creative BioMart, Creative Biostructure, Creative Enzymes, Absolute Antibody, EUCODIS Bioscience, Fusion Antibodies, Innovagen, ZYMVOL, Averring Biotech, EnzymeWorks, GeNext Genomics and Quantumzyme. This protein engineering market report includes an easily searchable excel database of all the protein engineering companies, worldwide.
Amongst other elements, the market report features:
Several recent developments have taken place in the field of protein engineering. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.